Pneumatic Nebulizers Market To Reach $1,166.74 Million By 2030

Pneumatic Nebulizers Market Growth & Trends

The global pneumatic nebulizers market size is expected to reach USD 1,166.74 million by 2030, registering a CAGR of 6.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market has shown constant growth in the adoption of pneumatic nebulizers as home healthcare devices have been gaining popularity in recent years. Miniaturization of products and technological advancements are also boosting the adoption of home healthcare devices.

As per the Minnesota Department of Health, administration of medication through nebulizer represents a lower infection risk as compared to other aerosol-producing procedures. On the other hand, according to ISAM, aerosols from the nebulizer do not carry viral particles derived from the patient as they are generated from the fluid in the nebulized chamber, which is a non-patient source. Aerosols generated by nebulizers comprise pathogens only when the healthcare workers or patients contaminate the nebulizers. Various recommendations from institutes do not clarify whether it is appropriate to use nebulizers during the pandemic.

However, there are no known cases of passive infection due to nebulizers. Also, the risk of infection, if any, can be avoided if proper COVID-19 precautions are taken. Therefore, the pandemic affected the overall market only to a certain extent. Revolutionary technological progress is rapidly transforming the market. These expansions are producing lucrative potentials. For instance, in March 2019, Breath Technologies announced the initiation of Phase 3 BOSTON clinical study of L-CsA-i for the treatment of bronchiolitis obliterans syndrome via a drug-specific eFlow nebulizer of PARI Pharma that is under investigation.

 Request a free sample copy or view report summary: Pneumatic Nebulizers Market Report

Pneumatic Nebulizers Market Report Highlights

• Based on indication, the breath-actuated segment held the largest revenue share 64.06% in 2024. Breath-actuated nebulizers elucidate higher drug delivery capacity and lesser dosage wastage features. Thus, the segment delivering advanced inhalation therapy is expected to dominate the market over the forecast period.

• Hospitals & clinics segment held the largest market share in 2024. The increasing adoption of pneumatic nebulizers for the management of acute respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD) is fueling the segment growth.

• North America pneumatic nebulizers market dominated with a revenue share of 35.28% in 2024 and is poised to grow over the forecast period owing to the increasing prevalence of respiratory diseases and advancements in nebulizer technology.

• Asia Pacific is expected to grow at the fastest CAGR over the forecast period. The burden of COPD in Asia is greater than that in developed Western countries.

Pneumatic Nebulizers Market Segmentation

Grand View Research has segmented the global pneumatic nebulizers market on the basis of on indication, end-use, and region:

Pneumatic Nebulizers Indication Outlook (Revenue, USD Million, 2018 - 2030)

• Breath-actuated

• Vented

Pneumatic Nebulizers End-use Outlook (Revenue, USD Million, 2018 - 2030) 

• Hospitals & Clinics    

• Home Healthcare

Pneumatic Nebulizers Regional Outlook (Revenue, USD Million, 2018 - 2030) 

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Norway

  • Denmark

  • Sweden

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Pneumatic Nebulizers Market

• Koninklijke Philips N.V.

• OMRON Corporation

• PARI GmbH

• General Electric

• Allied Healthcare Products, Inc.

• BD (Becton, Dickinson & Company)

• GF Health Products, Inc.

• Medline Industries, LP

• Briggs Healthcare

• Vectura Group Ltd